Reduction of cell proliferation and enhancement of NK-cell activity

• US 5,082,833 A
• Filed: 06/30/1988
• Issued: 01/21/1992
• Est. Priority Date: 06/30/1988
• Status: Expired due to Term

• Current Assignee: Abulkalam M. Shamsuddin
• Original Assignee: Abulkalam M. Shamsuddin
• Inventors: Shamsuddin, Abulkalam M.
• Primary Examiner(s): FRIEDMAN, STANLEY
• Application Number:
  US07/213,889
• Time in Patent Office: 1,300 Days
• Field of Search: 514/143, 514/729
• US Class Current: 514/143
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/047 having two or more hydroxy groups, e.g. sorbitol
• CPC Class Codes: A61K 31/66 Phosphorus compounds
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/04 Immunostimulants

Abstract

A method for moderating the rate of cellular mitosis in a living mammalian tissue having a pathologically elevated rate of cellular mitosis sensitive to treatment with a solution below which comprises perfusing said tissue under mitotic growth conditions with a safe and effective amount and concentration of a composition consisting essentially of a) inositol hexaphosphate or a physiologically acceptable salt thereof; and b) a source of inositol or a physiologically acceptable salt thereof, for a period of time sufficient to moderate the elevated rate of cellular mitosis to a normal, non-pathological rate for said tissue. The method is useful in human and mammalian diseases wherein NK cell activity is altered in the laboratory, e.g. tumors, other cancers including leukemia, immunosuppressed individuals (AIDS and transplant recipients), and in viral, fungal or protozoal infections.

Claims

1. A method for moderating the rate of cellular mitosis in a living mammal having a pathologically elevated rate of cellular mitosis, which comprises administering to the mammal a safe and effective amount of solution of a) inositol hexaphosphate or a physiologically acceptable salt thereof;

and b) inositol or a physiologically acceptable salt thereof, in a molar ratio of a);

b) from about 1;

3 to 3;

1 effective to moderate the elevated rate of cellular mitosis to a normal, non-pathological rate.

2. A method of claim 1, wherein the molar ratio is 1:

1.

3. A method according to claim 1, wherein the composition is administered parenterally.

4. A method according to claim 1, wherein the composition is administered orally.

5. A method according to claim 1, wherein the pathological elevated rate of cellular mitosis is caused by cancer or precancer.

6. A method according to claim 5, wherein the cancer is a blood cancer.

7. A method according to claim 5, wherein the cancer is large intestinal cancer.

8. A method for enhancing the rate of KN cell activity in a living mammal having a pathologically or pharmaceutically decreased rate of tumoricidal activity and reduced NK cell activity, which comprises administering to the mammal an amount of a solution of a) inositol hexaphosphate or a physiologically acceptable salt thereof;

and b) inositol or a physiologically acceptable salt thereof, in a molar ratio of a);

b) of about 1;

3 to 3;

1, effective to enhance the rate of NK-cell activity to a normal, non-pathological rate.

9. A method according to claim 8, wherein the molar ration is about 1:

1.

10. A method according to claim 8, wherein the composition is administered parenterally.

11. A method according to claim 8, wherein the composition is administered orally.

12. A method according to claim 8, wherein the decreased rate of NK-cell activity is caused by immunosuppression.

13. A method according to claim 12, wherein the immunosuppression is caused by an AIDS-related infection.

14. A method according to claim 12, wherein the immunosuppression is pharmaceutically induced by chemotherapy or in preparation for receiving a tissue transplant.

15. A method according to claim 12, wherein the immunosuppression is caused by a bacterial, viral, fungal, or protozoal infection.

16. A pharmaceutical composition capable of a) moderating the rate of cellular mitosis in a living mammal having a pathologically elevated rate of cellular mitosis or b) enhancing the rate of NK cell activity in a living mammal having a pathologically or pharmaceutically decreased rate of tumoricidal activity, which comprises a safe and effective amount and concentration per unit dosage of a composition consisting essentially of a) inositol hexaphosphate or a physiologically acceptable salt thereof;

and b) inositol or a physiologically acceptable salt thereof in a molar ratio of a);

b) of about 1;

3 to 3;

1.

17. A composition according to claim 16, wherein the molar ratio of a):

b) is about 1;

1.

18. A composition according to claim 16, as a sterile liquid adapted for parenteral administration.

19. A composition according to claim 16, as a solid adapted for oral administration.

20. A composition according to claim 16, as a liquid adapted for oral administration.